Multiomics Market: Market Size & Forecast 2026

Multiomics refers to the combined analysis of multiple high-throughput 'omics' data types, most commonly genomics, transcriptomics, proteomics, and metabolomics, to capture a more complete picture of biology than any single layer can provide. Independent industry estimates place the 2025 global market in the USD 2.6-3.8 billion range, with midpoints clustering around USD 3.1-3.2 billion, and consensus annual growth rates between 12% and 16%. No government statistical agency publishes official revenue figures for this market; size estimates are produced entirely by private market research firms.

• •Consensus 2025 market value: approximately USD 3.14 billion, with most estimates between USD 2.95 billion and USD 3.75 billion.
• •Consensus CAGR through the early 2030s: roughly 14.87%, implying a market of USD 10-13 billion by 2034-2035.
• •Demand is anchored in pharmaceutical R&D, academic and translational research, and emerging clinical applications in oncology and rare disease.

The steep decline in next-generation sequencing and mass spectrometry costs has made joint profiling of multiple molecular layers economically feasible for routine research use. Pharmaceutical companies are increasingly adopting multiomics to improve target identification, biomarker discovery, and patient stratification, which is expanding the addressable customer base beyond academic core facilities. At the same time, AI and machine-learning tools capable of integrating heterogeneous datasets are turning raw multiomics output into actionable insight, accelerating commercialization.

• •Plummeting costs of sequencing and high-throughput proteomics platforms (e.g., Olink, Standard BioTools/SomaLogic) are lowering barriers to multi-layer studies.
• •Rising pharma and biotech R&D budgets for precision medicine and biomarker-driven clinical trials are expanding demand.
• •Public research funding from agencies such as the NIH, the EU's Horizon programs, and national genomics initiatives continues to underwrite large-scale multiomics consortia.

By product type, the market spans instruments and platforms, consumables and reagents, software and services, with consumables typically representing the largest and most recurring revenue stream. By application, oncology remains the dominant use case, followed by neurology, immunology, and infectious disease research. North America leads on the back of concentrated pharmaceutical R&D spending and NIH-funded programs, while Asia-Pacific is the fastest-growing region due to expanding genomics infrastructure in China, Japan, South Korea, and India.

• •By omics layer, genomics and transcriptomics hold the largest share, while proteomics and metabolomics are the fastest-growing subsegments.
• •By end user, pharmaceutical and biotechnology companies are the largest customers, ahead of academic and clinical research institutes.
• •North America accounts for the majority of 2025 revenue, but Asia-Pacific is projected to grow at the highest CAGR through 2032-2035.

What are the recent trends and outlook?

Single-cell and spatial multiomics are moving from research novelty to commercial standard, enabling researchers to profile thousands of cells across multiple molecular layers in a single experiment. AI-driven integrative analytics, including foundation models trained on multiomics data, are emerging as a distinct product category rather than a feature bundled into existing platforms. Cloud-native bioinformatics providers are also lowering the compute barrier for hospitals and smaller biotechs, which is expected to broaden the customer base beyond top-tier research centers.

• •Single-cell and spatial multiomics platforms are the fastest-growing technology subsegment and a key battleground for incumbents and challengers alike.
• •AI and foundation models for multiomics data integration are attracting significant venture investment and shaping new product roadmaps.
• •Clinical translation, particularly in oncology, rare disease, and pharmacogenomics, represents the largest long-term upside but also the most demanding regulatory and reimbursement hurdle.